News
-
Nano PharmaSolutions and CDMO Mikart have announced limited data from an ongoing Phase 1 trial of Nano PharmaSolutions’ NT-301 apomorphine nasal powder, which is in development for the treatment of OFF episodes in Parkinson’s disease.… Read more . . .
-
Polyrizon announced that it has submitted a pre-submission package to the FDA for its PL-14 Allergy Blocker nasal spray. The company describes the product as “a novel, non-invasive nasal spray that forms a physical barrier… Read more . . .
-
According to ARS Pharmaceuticals, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved 1mg and 2mg doses of neffy epinephrine nasal spray for the treatment of anaphylaxis in people who weigh more than 15 kilograms.… Read more . . .
-
AstraZeneca announced that the FDA has approved the company’s supplemental NDA to add data related to the treatment of mild asthma to the label for Airsupra albuterol / budesonide MDI. In October 2024, AstraZeneca and… Read more . . .
-
Neumifil antiviral nasal spray developer Pneumagen has announced the launch of a platform called NeumoBind for intranasal protein formulations. The company says, “By anchoring proteins in place on a mucosal surface, NeumoBind addresses a critical… Read more . . .
-
According to Corstasis Therapeutics, the FDA has approved the company’s NDA for Enbumyst (RSQ-777) bumetanide nasal spray for the treatment of edema associated with heart, kidney, and liver disease. In January 2025, Corstasis announced that… Read more . . .
-
Inhaled mRNA developer Ethris and CDMO Evonik have announced a new partnership for development and commercialization of a lipid nanoparticle (LNP) platform for delivery of nucleic acid. Ethris’s SNaP LNP technology will become available to… Read more . . .
-
Strides Pharma Science announced a new development agreement between Strides Pharma Global and OINDP specialist CDMO Kenox Pharmaceuticals for “multiple nasal spray products for the US market across diverse therapeutic indications.” The company did not… Read more . . .
-
According to Pulmovant, the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Pulmovant’s inhaled dry powder mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).… Read more . . .
-
Phase 2 study finds azelastine nasal spray significantly reduced SARS-CoV-2 and rhinovirus infection
Saarland University announced that the Phase 2 CONTAIN study of azelastine nasal spray as a prophylactic against SARS-CoV-2 demonstrated a significant reduction in SARS-CoV-2 infection and also a reduction in rhinovirus infection for subjects using… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan